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Abstract
Background: Many patients with brain metastases from non-small cell lung cancer have limited survival, while
others survive for several years, depending on patterns of spread, EGFR and ALK alterations, among others. The
purpose of this study was to validate a new prognostic model (Lung-molGPA) originally derived from a North
American database.
Patients and methods: This retrospective study included 269 German and Norwegian patients treated with
individualized approaches, always including brain radiotherapy. Information about age, extracranial spread, number
of brain metastases, performance status, histology, EGFR and ALK alterations was collected. The Lung-molGPA score
was calculated as described by Sperduto et al.
Results: Median survival was 5.4 months. The score predicted survival in patients with adenocarcinoma histology
and those with other types. For example, median survival was 3.0, 6.2, 14.7 and 25.0 months in the 4 different
prognostic strata for adenocarcinoma. The corresponding figures were 2.4, 5.5 and 12.5 months in the 3 different
prognostic strata for non-adenocarcinoma.
Conclusions: These results confirm the validity of the Lung-molGPA in an independent dataset from a different
geographical region. However, median survival was shorter in 6 of 7 prognostic strata. Potential explanations
include lead time bias and differences in treatment selection, both brain metastases-directed and systemically.
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Introduction
One of the major challenges in the treatment of non-small
cell lung cancer (NSCLC) is the high risk of brain metas-
tases [1]. The continuous improvement of local treatment
options, e.g., surgery and radiosurgery, which has paral-
leled development of better systemic therapies, has re-
sulted in increasingly individualized approaches [2–6].
While some clinicians prefer simultaneous treatment of
radiologically visible macroscopic metastases and micro-
scopic disease, others recommend local therapy alone with
deferred salvage at the time of progression [7–9]. Efforts
are also being made to identify patients who can safely
continue systemic therapy without upfront brain radio-
therapy, and patients whose prognosis is so poor that best
supportive care should be considered [10–14]. Given that
brain metastases can occur early or late during the disease
trajectory, management decisions are not always simple
and straightforward [15].
Prognostic tools have long been used to support deci-
sion making and to stratify participants in prospective
clinical trials [16–19]. Scores such as the recursive parti-
tioning analysis (RPA) [20] or graded prognostic assess-
ment (GPA) [21, 22] have been validated in several studies
and adopted widely [20, 21]. Researchers have realized that
these tools should be updated to reflect unique biological
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features of different primary tumor types, e.g. for breast
and lung cancer [23–27]. Specifically for NSCLC a refined
score integrating molecular features (EGFR and ALK al-
terations; Lung-molGPA) has recently been developed by
a North American collaborative group, which previously
has published the GPA [28]. The purpose of the present
study was to validate the Lung-molGPA in an independent
European patient population, hypothesizing that a vali-
dated score would gain wide acceptance and could replace
the older RPA and GPA scores.
Material and methods
Patients and treatment
A retrospective study of 269 patients with irradiated brain
metastases from NSCLC was performed. Patients man-
aged with best supportive care rather than primary or
post-operative radiotherapy were excluded. Treatment
was individualized and consisted of focal therapies such as
surgery, radiosurgery and stereotactic fractionated ra-
diotherapy with or without whole-brain radiotherapy
(WBRT) or upfront WBRT alone with total doses in the
range of 20–40 Gy. Patients who failed to complete all
fractions of radiotherapy were also included. Salvage
treatment of intracranial lesions was individualized, too.
All approaches mentioned above were considered at the
time of relapse or progression. Systemic treatment was
usually prescribed as judged appropriate by the patients’
medical oncologists, both before and after brain-directed
treatments. The patients were treated between 2005
and 2015 and identified from a previously described data-
base [19, 29], which includes data from the radiotherapy
centers in Bodø and Freiburg. Prognosis was estimated on
the basis of age, Karnofsky performance status (KPS),
extracranial metastases, number of brain metastases and
NSCLC subtype as described in the original publication
[28] and shown in Table 1. Differences to the widely used
lung cancer-specific GPA score are also shown in the table.
Statistical methods
Actuarial survival from the first day of radiotherapy or
from surgery was calculated employing the Kaplan-Meier
method, and different groups were compared using the
log-rank test (SPSS 23, IBM Corp., Armonk, NY, USA).
Date of death was known in all patients. A multivariate
Cox regression analysis was also performed (forward
conditional method) and included all variables with p-
value ≤0.05 in univariate log-rank tests.
Results
Patient characteristics
The median age was 63 years (range 33–85). The me-
dian KPS was 80 (range 30–100). The most common ini-
tial treatment approach was primary WBRT alone (72%),
followed by surgery in combination with post-operative
Table 1 Baseline characteristics included in the Lung-molGPA
(Sperduto et al. 2016 [28]): minimum point sum 0 (poor





Brain metastases only 1 1
Age ≥70 years 0 0 if >60 years
Age <70 years 0.5 0.5 if 50–60 years,
1 if <50 years
Karnofsky performance status ≤70 0 0 if <70
Karnofsky performance status 80 0.5 0.5 if 70–80
Karnofsky performance status 90–100 1 1
Number of brain metastases >4 0 0 if >3
Number of brain metastases 1–4 0.5 0.5 if 2–3, 1 if 1
EGFR or ALK positive 1 not part of
the assessment
DS-GPA diagnosis-specific graded prognostic assessment [22]
Table 2 Patient characteristics
Parameter Number Percent
Male gender 155 58
Female gender 114 42
Adenocarcinoma 192 71
Non-adenocarcinoma 77 29
Extracranial metastases 176 65
No extracranial metastases 93 35
Single brain metastasis 54 20
2–4 brain metastases 86 32
>4 brain metastases 129 48
EGFR or ALK positive 19 7
Age <70 years 200 74
Age ≥70 years 69 26
KPS <70 52 19
KPS 70 70 26
KPS 80 50 19
KPS 90–100 97 36
Upfront whole brain radiotherapya 193 72
Upfront neurosurgery 57 21
Upfront radiosurgery 16 6
Upfront stereotactic fractionated radiotherapy 3 1
Supportive care alone 0 0
KPS Karnofsky performance status
aincludes patients with delayed (salvage) neurosurgery, radiosurgery,
fractionated re-irradiation
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radiotherapy (21%). Further patient characteristics are
shown in Table 2.
Lung-molGPA
Most patients had unfavorable prognostic features, i.e.
0–1 point in 110 patients (41%) and 1.5–2 points in
109 (41%). Forty-two patients (16%) had 2.5–3 points
and the remaining 8 (3%) had 3.5–4 points. These four
prognostic strata had significantly different median
survival of 2.8, 6.2, 14.0 and 25.0 months (p < 0.0001,
log-rank test pooled over all strata). Overall median
survival was 5.4 months. Table 3 shows the results of
univariate prognostic factors for survival. In multivari-
ate Cox regression analysis KPS (dichotomized variable
as in [28], p = 0.0001), extracranial metastases (p =
0.002), age (dichotomized variable as in [28], p = 0.05),
EGFR or ALK alteration (p = 0.001) and number of
brain metastases (dichotomized variable as in [28], p =
0.05) were significant predictors of survival. Figure 1
and Table 4 show the survival outcomes of patients
with adenocarcinoma. Figure 2 and Table 4 show the
corresponding data in case of non-adenocarcinoma
histology.
Discussion
We performed a retrospective validation study of the
Lung-molGPA [28] in a European patient population,
comparable to the previous validation of the DS-GPA
[29]. The study population consisted mainly of patients
with intermediate or poor prognosis who were judged
not to be appropriate candidates for aggressive local
therapies, such as surgery or stereotactic radiotherapy,
but received active brain-metastases-directed therapy.
This discrepancy likely explains why the median survival
in our study was 5.4 months, while the North American
Table 3 Univariate analysis of prognostic factors for overall
survival (log-rank test)
Parameter Median survival in months p-value
Male gender 5.5




No extracranial metastases 7.5 0.0001
1–4 brain metastases 6.0
>4 brain metastases 4.6 0.04
EGFR or ALK positive 22.9
Not EGFR or ALK positive 5.0 0.0001
Age <70 years 6.0
Age ≥70 years 3.0 0.006
KPS ≤70 2.5
KPS 80 7.0
KPS 90–100 11.0 0.0001
KPS Karnofsky performance status
Fig. 1 Actuarial survival of patients with adenocarcinoma stratified by Lung-molGPA, p = 0.0001 (pooled over all strata)
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patients survived for a median of 15.2 months (adeno-
carcinoma) and 9.2 months (non-adenocarcinoma).
Other treatments (chemotherapy, targeted drugs, salvage
of brain metastases) might have differed too, however,
they were not recorded in any of the studies. Neither
time interval from initial cancer diagnosis to brain me-
tastases nor diagnostic setting (imaging in asymptomatic
patients vs. clinical deficits) has been evaluated, resulting
in potential lead time bias if North American patients
were treated earlier. In principle, imbalances of patient
characteristics such as KPS or mutation status could
have contributed to the survival difference. However,
median survival was shorter in 6 of 7 prognostic strata
in our study. For example, patients with adenocarcinoma
had inferior survival in all 4 strata (median 3.0 vs.
6.9 months; median 6.2 vs. 13.7 months; median 14.7 vs.
26.5 months; median 25.0 vs. 46.8 months). For non-
adenocarcinoma the following differences emerged: me-
dian 2.4 vs. 5.3 months, median 5.5 vs. 9.8 months, and
median 12.5 vs. 12.8 months. Most of these differences
are clinically relevant and we therefore recommend add-
itional studies in patients managed with different ap-
proaches in different regions of the world. The main
result of our study was that the Lung-molGPA accur-
ately reflects the prognostic impact of different baseline
characteristics. This score seems to represent a useful
improvement of its widely adopted ancestors such as
RPA and DS-GPA [20–22].
Limitations of this study, which followed the methods
used by Sperduto et al. [28], include the number of pa-
tients, statistical power of subgroup analyses, and retro-
spective design. Whereas the number of patients was
limited in our database, they represent the total cohort
of the two radiotherapy departments and consequently
Table 4 Survival outcomes stratified by Lung-molGPA
Group Number Median survival in months 6-month probability 12-month probability
Adeno 0–1 p. 80 3.0 26 10
Adeno 1.5–2 p. 80 6.2 54 34
Adeno 2.5–3 p. 25 14.7 84 64
Adeno 3.5–4 p. 8 25.0 100 88
Other 0–1 p. 30 2.4 10 10
Other 1.5–2 p. 29 5.5 48 21
Other 2.5–3p. 18 12.5 78 56
Fig. 2 Actuarial survival of patients with non-adenocarcinoma stratified by Lung-molGPA, p = 0.0001 (pooled over all strata)
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express the daily practice at these academic hospitals.
Given that patients managed with best supportive care
were excluded, worse survival outcomes could be ex-
pected if one would analyze all patients with a brain me-
tastases diagnosis, or in radiation oncology practices that
would have offered WBRT to patients who were man-
aged with best supportive care at the two institutions
that participated in this study. The North American
database included 2186 patients treated between 2006
and 2014. Radiosurgery was a component of care in
more than 50% of patients with adenocarcinoma. In
addition, neurosurgical resection was performed in se-
lected patients. In our study, less than 30% received up-
front surgery, radiosurgery or stereotactic fractionated
radiotherapy. We have previously reported that increas-
ing use of focal treatments such as radiosurgery and sur-
gical resection and also of systemic treatment has
resulted in prolonged survival, especially for patients
with favorable prognostic features [30]. The observed
survival differences between the present study and the
one reported by Sperduto et al. [28] are in line with the
hypothesis that continuous improvements of multimodal
care translate into better outcome. With the advent of
targeted drugs with high efficacy in molecularly-defined
subgroups [10, 11, 31], and possibly also immunotherapy
[32], further improvement can be expected.
Conclusions
The data presented in this study confirm the validity of
the Lung-molGPA in patients from a different geograph-
ical region. However, median survival was shorter in 6 of
7 prognostic strata. Potential explanations include dif-
ferences in treatment selection, both brain metastases-
directed and with systemic agents. These hypotheses
require additional studies.
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